MARKET

TELA

TELA

TELA BIO, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.66
-0.03
-0.18%
Opening 11:17 11/25 EST
OPEN
16.71
PREV CLOSE
16.69
HIGH
16.80
LOW
16.66
VOLUME
1.41K
TURNOVER
--
52 WEEK HIGH
23.55
52 WEEK LOW
5.25
MARKET CAP
240.44M
P/E (TTM)
-7.0791
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
TELA Bio to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference
MALVERN, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Conference Dates: Tuesday, December 1 to Thursday, December 3, 2020. A link to the fireside chat presentation is available on the "Investors" section of the Company's website at ir.telabio.com.About TELA Bio, Inc.TELA Bio, Inc. is a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.TELA Bio Contact Stuart Henderson Vice President, Corporate Development and Investor Relations TELA Bio, Inc. 484-320-2930 Investor Contact Greg Chodaczek 347-620-7010  ir@telabio.com
GlobeNewswire · 1d ago
Recap: TELA Bio Q3 Earnings
Shares of TELA Bio (NASDAQ:TELA) were flat after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 97.65% over the past year to ($0.53), which missed the estimate of ($0.49).Revenue of $5,313,000 higher by 33.73% year over year, which beat the estimate of $4,580,000.Guidance Earnings guidance hasn't been issued by the company for now.TELA Bio hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 11, 2020View more earnings on TELATime: 04:30 PMET Webcast URL: https://edge.media-server.com/mmc/p/4ajr9xe6Technicals Company's 52-week high was at $23.55Company's 52-week low was at $5.25Price action over last quarter: Up 18.62%Company Description TELA Bio Inc is a United States-based medical technology company. It is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 11, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/11 21:34
TELA Bio EPS misses by $0.09, beats on revenue
TELA Bio (TELA): Q3 GAAP EPS of -$0.53 misses by $0.09.Revenue of $5.31M (+33.8% Y/Y) beats by $0.73M.Press Release
Seekingalpha · 11/11 21:13
TELA Bio Q3 EPS $(0.53) Misses $(0.49) Estimate, Sales $5.30M Beat $4.58M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.49) by 8.16 percent. This is a 97.65 percent increase over losses of $(22.58) per share from the
Benzinga · 11/11 21:11
TELA Bio Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 11, 2020 / TELA Bio Inc (NASDAQ:TELA) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 11, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 11/11 19:30
Additional data shows durable outcome for TELA Bio' tissue matrix for hernia repair
TELA Bio (TELA) has announced additional data from its BRAVO study with OviTex tissue matrix. Data were presented at the Americas Hernia Society Annual Meeting.30-day data from 85 subjects demonstrated that ventral hernia
Seekingalpha · 09/25 11:59
TELA Bio Highlights Presentation Of Additional Data From BRAVO Study Of OviTex For Ventral Hernia Repair
MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcementMALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc.
Benzinga · 09/25 11:02
TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair
MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that
GlobeNewswire · 09/25 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TELA. Analyze the recent business situations of TELA BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TELA stock price target is 20.00 with a high estimate of 22.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 62
Institutional Holdings: 9.75M
% Owned: 67.59%
Shares Outstanding: 14.43M
TypeInstitutionsShares
Increased
16
511.04K
New
17
-12.19K
Decreased
15
646.28K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.94%
Healthcare Equipment & Supplies
-0.58%
Key Executives
Chairman/Independent Director
Kurt Azarbarzin
Chairman/Independent Director
Douglas Evans
President/Chief Executive Officer/Co-Founder/Director
Antony Koblish
Co-Founder
Maarten Persenaire
Chief Technology Officer
Skott Greenhalgh
Chief Financial Officer
Nora Brennan
Chief Technology Officer
Ellis Greenhalgh
Other
Peter Murphy
Independent Director
kurt Azarbarzin
Independent Director
Vince Burgess
Independent Director
Lisa Colleran
Independent Director
Federica OBrien
Independent Director
Adele Oliva
Independent Director
Matt Zuga
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TELA
TELA Bio Inc. is a medical technology company. The Company is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. It offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), can be used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of TELA Bio Inc stock information, including NASDAQ:TELA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TELA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TELA stock methods without spending real money on the virtual paper trading platform.